Clinical characteristics and influencing factors in type 2 diabetes mellitus patients with MAFLD at moderate-to-high risk of metabolic-associated fatty liver fibrosis
Medical Journal of Chinese People′s Liberation ArmyVol. 50, Issue 11, Pages: 1366-1373(2025)
Clinical Research|更新时间:2025-12-11
分享给微信好友或者朋友圈
导出参考文献
Clinical characteristics and influencing factors in type 2 diabetes mellitus patients with MAFLD at moderate-to-high risk of metabolic-associated fatty liver fibrosis
“The latest research reveals that gender, BUN, Cr, LDL-C, FT3 and FT4 are independent influencing factors of high risk of liver fibrosis in type 2 diabetes patients with metabolic fatty liver disease.”
作者机构:
上海中医药大学附属第七人民医院内分泌科,上海 200120
作者简介:
E-mail: wendylee_tcm@shutcm.edu.cn
基金信息:
National Natural Science Foundation of China(82074178);the Shanghai Municipal Health Commission's "14th Five-Year Plan" Project for Enhancing the Construction of Traditional Chinese Medicine Specialties and Emergency Care Capacity(ZYTSZK2-18);the Shanghai Municipal Health Commission's Initiative for Establishing an Integrated Traditional Chinese and Western Medicine Service System for Regional Diagnosis and Treatment of Xiaoke Disease, the Clinical Specialty Discipline Development Program of the Pudong New Area Health Commission;the Leading Talent Training Program of the Pudong New Area Health Commission(PWYts2021-13)
Liu Xuan,Li Chang,Zhang Hong-Li,et al.Clinical characteristics and influencing factors in type 2 diabetes mellitus patients with MAFLD at moderate-to-high risk of metabolic-associated fatty liver fibrosis[J].Medical Journal of Chinese People′s Liberation Army,2025,50(11):1366-1373.
Liu Xuan,Li Chang,Zhang Hong-Li,et al.Clinical characteristics and influencing factors in type 2 diabetes mellitus patients with MAFLD at moderate-to-high risk of metabolic-associated fatty liver fibrosis[J].Medical Journal of Chinese People′s Liberation Army,2025,50(11):1366-1373. DOI: 10.11855/j.issn.0577-7402.1948.2025.0811.
Clinical characteristics and influencing factors in type 2 diabetes mellitus patients with MAFLD at moderate-to-high risk of metabolic-associated fatty liver fibrosis